Donors, donors, and more donors

Blood

Volumn 114, Issue 18, 2009, Pages 3721-3722

  Anderlini, Paolo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DONOR; DONOR SELECTION; FOLLOW UP; HUMAN; NOTE; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 77950379013     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-239103     Document Type: Note

References (7)

1. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48(7):1495-1501.
2. Tigue C, McKoy J, Evens A, Trifilio S, Tallman M, Bennett C. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transpl. 2007;40:185-192.
3. Bennett C, Evens A, Andritsos L, et al. Hematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006;135(5):642-650.
4. Hölig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114(18):3757-3763.
5. Confer L, Miller J. Long-term safety of filgrastim (rhGCSF) administration. Br J Haematol. 2007;137(1):77-78.
6. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant. 1996;17(suppl 2): S28-S30.
7. Anderlini P, Champlin R. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111(4):1767-1772.